Risedronic acid is primarily used in the treatment of bone-related disorders, particularly osteoporosis in postmenopausal women and men. It helps to increase bone mass and reduce the risk of fractures by inhibiting bone resorption. Additionally, it is effective in managing Paget's disease, a condition characterized by abnormal bone remodeling. The medication is also prescribed to prevent bone loss in patients undergoing long-term corticosteroid therapy. It is typically administered orally in tablet form, with specific instructions to ensure optimal absorption and minimize gastrointestinal side effects. Regular monitoring of bone density and kidney function is recommended during treatment.